ECSP12012138A - Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello - Google Patents

Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello

Info

Publication number
ECSP12012138A
ECSP12012138A ECSP12012138A ECSP12012138A EC SP12012138 A ECSP12012138 A EC SP12012138A EC SP12012138 A ECSP12012138 A EC SP12012138A EC SP12012138 A ECSP12012138 A EC SP12012138A
Authority
EC
Ecuador
Prior art keywords
cdmab
antibodies
neck
head
binding fragments
Prior art date
Application number
Other languages
English (en)
Inventor
Cruz Luis A G Da
Elizabeth Jane Franzmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012138(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP12012138A publication Critical patent/ECSP12012138A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Esta invención se relaciona con el estadiaje, diagnóstico y tratamiento contra enfermedades cancerosas (tanto tumores primarios como metástasis tumorales), particularmente a la mediación de citotoxicidad de células tumorales; y más particularmente al uso de anticuerpos monoclónicos, fragmentos de unión al antígeno de lo mismo, y/o anticuerpos modificadores de enfermedad cancerosa (CDMAB), opcionalmente combinados con uno o más CDMAB, con agentes quimioterapéuticos y conjugados de lo mismo, como unos medios para iniciar una respuesta citotóxica a carcinomas escamocelulares de cabeza y cuello en humano. La invención adicionalmente se relaciona con inmunoensayos que utilizan anticuerpos monoclónicos, fragmentos de unión al antígeno de lo mismo, y/o CDMAB de la invención actual. Los anticuerpos modificadores de enfermedad cancerosa pueden conjugarse a toxinas, enzimas, compuestos radiactivos, citocinas, interferón, porciones con especificidad de objetivo o indicadoras y células hematógenas. En aspectos particulares, el CDMAB usado en los métodos de la invención es un anticuerpo anti-CD44, que puede ser el anticuerpo producido por el hibridoma depositado con el ATCC que tiene el número de acceso PTA-4621 y/o una versión quimérica o humanizada del mismo.
ECSP12012138 2010-02-04 2012-09-04 Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello ECSP12012138A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30144910P 2010-02-04 2010-02-04

Publications (1)

Publication Number Publication Date
ECSP12012138A true ECSP12012138A (es) 2012-09-28

Family

ID=43858306

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012138 ECSP12012138A (es) 2010-02-04 2012-09-04 Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello

Country Status (30)

Country Link
US (2) US20130224108A1 (es)
EP (1) EP2531527B1 (es)
JP (2) JP5763105B2 (es)
KR (1) KR20130042466A (es)
CN (1) CN102741292B (es)
AU (1) AU2011212485B2 (es)
BR (1) BR112012019475A8 (es)
CA (1) CA2786337A1 (es)
CL (1) CL2012001980A1 (es)
CR (1) CR20120429A (es)
DK (1) DK2531527T3 (es)
EC (1) ECSP12012138A (es)
ES (1) ES2460945T3 (es)
HR (1) HRP20140513T1 (es)
IL (1) IL220092A (es)
MA (1) MA34010B1 (es)
MX (1) MX2012008699A (es)
MY (1) MY157532A (es)
NZ (1) NZ600079A (es)
PE (1) PE20130380A1 (es)
PH (1) PH12012501525A1 (es)
PL (1) PL2531527T3 (es)
PT (1) PT2531527E (es)
RS (1) RS53327B (es)
RU (1) RU2599447C2 (es)
SG (2) SG182704A1 (es)
SI (1) SI2531527T1 (es)
TW (1) TW201130512A (es)
WO (1) WO2011095498A1 (es)
ZA (1) ZA201205649B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2531527T3 (da) * 2010-02-04 2014-05-05 Hoffmann La Roche Monoklonalt antistof til cd44 til anvendelse i behandlingen af hoved-hals-pladeepitelcarcinom
KR20140090997A (ko) * 2011-10-26 2014-07-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 B-세포 만성 림프구성 백혈병 및 다른 혈액학적 악성종양의 치료를 위한 cd44 단일클론 항체
US20140335084A1 (en) * 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
WO2014198843A1 (en) * 2013-06-12 2014-12-18 F. Hoffmann-La Roche Ag Markers for responsiveness to anti-cd44 antibodies
KR102320503B1 (ko) * 2013-07-31 2021-11-03 더 유니버시티 오브 마이애미 대상체에서 암 위험을 동정하는 조성물 및 방법
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
KR102215384B1 (ko) * 2014-06-11 2021-02-15 (재) 스크립스코리아항체연구원 CD44v3 도메인 3 및 도메인 6 특이적 단일클론 항체 및 그 용도
TWI535452B (zh) 2015-01-23 2016-06-01 長庚醫療財團法人 使用抗－ｃｄ４４中和抗體來治療和／或預防心房顫動
JP7212138B2 (ja) 2018-07-20 2023-01-24 ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド 抗ｃｄ４０抗体及びその使用
EP4114860A1 (en) * 2020-03-06 2023-01-11 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2021233962A1 (en) 2020-05-19 2021-11-25 Institut Curie Methods for the diagnosis and treatment of cytokine release syndrome
US20250326855A1 (en) * 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2026032937A1 (en) * 2024-08-06 2026-02-12 Institut National de la Santé et de la Recherche Médicale Inhibitor of cd44 for use in the treatment of alcohol-related liver disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE19545472A1 (de) * 1995-12-06 1997-06-12 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20030103985A1 (en) * 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
HUP0400030A3 (en) 2001-05-18 2006-02-28 Boehringer Ingelheim Pharma Antibodies specific for cd44v6
WO2004024750A2 (en) * 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
DK2531527T3 (da) * 2010-02-04 2014-05-05 Hoffmann La Roche Monoklonalt antistof til cd44 til anvendelse i behandlingen af hoved-hals-pladeepitelcarcinom

Also Published As

Publication number Publication date
SG182704A1 (en) 2012-08-30
RU2012137380A (ru) 2014-03-10
CA2786337A1 (en) 2011-08-11
NZ600079A (en) 2013-07-26
SI2531527T1 (sl) 2014-07-31
MA34010B1 (fr) 2013-02-01
ES2460945T3 (es) 2014-05-16
IL220092A (en) 2016-02-29
PH12012501525A1 (en) 2017-07-26
RU2599447C2 (ru) 2016-10-10
AU2011212485B2 (en) 2014-04-17
JP2015155409A (ja) 2015-08-27
CN102741292B (zh) 2015-10-21
MX2012008699A (es) 2012-09-12
PE20130380A1 (es) 2013-03-30
BR112012019475A2 (pt) 2017-01-10
MY157532A (en) 2016-06-15
TW201130512A (en) 2011-09-16
IL220092A0 (en) 2012-09-24
KR20130042466A (ko) 2013-04-26
RS53327B (sr) 2014-10-31
AU2011212485A1 (en) 2012-07-19
WO2011095498A1 (en) 2011-08-11
PT2531527E (pt) 2014-05-16
JP6037149B2 (ja) 2016-11-30
US20130224108A1 (en) 2013-08-29
BR112012019475A8 (pt) 2017-12-26
SG10201505118PA (en) 2015-07-30
DK2531527T3 (da) 2014-05-05
JP2013518848A (ja) 2013-05-23
JP5763105B2 (ja) 2015-08-12
EP2531527B1 (en) 2014-03-19
CN102741292A (zh) 2012-10-17
ZA201205649B (en) 2015-01-28
HRP20140513T1 (hr) 2014-07-18
PL2531527T3 (pl) 2014-08-29
US20150374848A1 (en) 2015-12-31
EP2531527A1 (en) 2012-12-12
CL2012001980A1 (es) 2012-11-23
CR20120429A (es) 2012-12-06

Similar Documents

Publication Publication Date Title
ECSP12012138A (es) Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
CO6140062A2 (es) Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas
CL2020003046A1 (es) Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018)
PH12021552831A1 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MY205343A (en) Anti-muc1 antibody
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
CO6241160A2 (es) Anticuerpos anti-cd44 quiméricos y humanizados que median la citotoxicidad de celulas de cancer
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
RU2016150377A (ru) Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc
CU20130130A7 (es) Anticuerpos tipo receptor de células t específicos para un péptido wt1 presentado por hla-a2
WO2019112347A3 (ko) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
RU2016143552A (ru) Гуманизированные антитела к антигену Томсена-Фриденрайха
EP4032550A3 (en) Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
ZA202008095B (en) Humanized antibodies against psma
AR077972A1 (es) Anticuerpos contra cdcp1 destinados al tratamiento del cancer
MX2022005816A (es) Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70.
MX2010001637A (es) Mediacion de citotoxicidad de celulas que evidencian la expresion superficial de cd9.
CO2023013550A2 (es) Polipéptido de unión a gucy2c y usos del mismo
AR070279A1 (es) Anticuerpos modificadores de enfermedades cancerosas (cdma)
MX2009001642A (es) Metodos para el tratamiento de leucemia de mieloide aguda.